Squarepoint Ops LLC Grows Position in Exelixis, Inc. (NASDAQ:EXEL)

Squarepoint Ops LLC increased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 242.8% during the second quarter, Holdings Channel reports. The fund owned 89,449 shares of the biotechnology company’s stock after acquiring an additional 63,352 shares during the quarter. Squarepoint Ops LLC’s holdings in Exelixis were worth $2,010,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Resonant Capital Advisors LLC increased its stake in Exelixis by 3.6% during the second quarter. Resonant Capital Advisors LLC now owns 13,746 shares of the biotechnology company’s stock worth $309,000 after acquiring an additional 477 shares during the last quarter. Cornercap Investment Counsel Inc. grew its stake in Exelixis by 1.1% during the second quarter. Cornercap Investment Counsel Inc. now owns 50,497 shares of the biotechnology company’s stock worth $1,135,000 after buying an additional 539 shares during the period. Alaska Permanent Fund Corp increased its position in shares of Exelixis by 1.2% in the first quarter. Alaska Permanent Fund Corp now owns 53,239 shares of the biotechnology company’s stock worth $1,263,000 after acquiring an additional 617 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Exelixis by 232.6% during the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 728 shares in the last quarter. Finally, Banque Cantonale Vaudoise boosted its position in Exelixis by 11.5% during the 1st quarter. Banque Cantonale Vaudoise now owns 7,555 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 781 shares during the period. Hedge funds and other institutional investors own 85.27% of the company’s stock.

Insider Transactions at Exelixis

In other news, CFO Christopher J. Senner sold 125,000 shares of the company’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the completion of the transaction, the chief financial officer now owns 721,680 shares in the company, valued at $19,622,479.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Exelixis news, CFO Christopher J. Senner sold 125,000 shares of the firm’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $27.19, for a total transaction of $3,398,750.00. Following the transaction, the chief financial officer now owns 721,680 shares of the company’s stock, valued at approximately $19,622,479.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Dana Aftab sold 95,000 shares of the stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $25.00, for a total transaction of $2,375,000.00. Following the completion of the transaction, the executive vice president now owns 520,990 shares of the company’s stock, valued at $13,024,750. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 327,858 shares of company stock worth $8,640,129. 2.85% of the stock is currently owned by company insiders.

Exelixis Trading Down 1.0 %

EXEL stock opened at $26.24 on Friday. The stock’s 50 day simple moving average is $25.79 and its 200 day simple moving average is $23.55. Exelixis, Inc. has a 12-month low of $18.64 and a 12-month high of $27.83. The firm has a market cap of $7.96 billion, a P/E ratio of 41.00, a P/E/G ratio of 0.56 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, August 6th. The biotechnology company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.31 by $0.44. Exelixis had a net margin of 17.38% and a return on equity of 15.54%. The company had revenue of $637.18 million for the quarter, compared to analysts’ expectations of $468.21 million. On average, research analysts forecast that Exelixis, Inc. will post 1.59 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on EXEL shares. Oppenheimer restated an “outperform” rating and set a $29.00 price objective on shares of Exelixis in a research note on Tuesday, July 30th. Truist Financial reissued a “buy” rating and set a $33.00 price target (up from $32.00) on shares of Exelixis in a research report on Thursday, August 8th. UBS Group started coverage on shares of Exelixis in a research note on Thursday, September 19th. They set a “neutral” rating and a $30.00 price objective on the stock. StockNews.com raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 13th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $27.00 price target on shares of Exelixis in a report on Thursday, September 26th. Five research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Exelixis currently has a consensus rating of “Moderate Buy” and an average target price of $27.67.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.